A mitochondria-derived peptide encoded within the 16S rRNA sequence that protects against neurodegeneration, insulin resistance, and cellular apoptosis.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →Humanin is a 24-amino acid microprotein with an origin story unlike any other peptide in this field. It was discovered in 2001 by a Japanese research team led by Nishimoto and colleagues, who were searching for genes expressed in neurons that had somehow survived the neurodegeneration of Alzheimer’s disease. When they screened a cDNA library derived from preserved occipital cortex neurons of Alzheimer’s patients, they identified a small open reading frame that encoded a peptide capable of protecting cells from amyloid-beta-induced death. They named it Humanin — a name that carries a certain poetry, given that it was found in the brain cells that had endured.
What makes Humanin truly extraordinary from a biological standpoint is where its gene resides. Humanin is encoded within the 16S ribosomal RNA gene of the mitochondrial genome — not the nuclear genome. This places it in an emerging category called mitochondrial-derived peptides (MDPs), a class of small proteins translated from small open reading frames within mitochondrial DNA that were largely overlooked for decades because researchers weren’t expecting protein-coding sequences in what appeared to be structural RNA genes. Humanin was the first MDP identified, and its discovery opened a new chapter in mitochondrial biology.
As a mitochondrially-encoded peptide, Humanin sits at the intersection of mitochondrial function, cellular survival signaling, and systemic metabolic regulation. Circulating levels of Humanin in the bloodstream decline with age in humans — a pattern that parallels the age-related decline in mitochondrial function and is inversely correlated with several disease risk markers. This age-related decline has generated significant interest in Humanin as a potential longevity-associated peptide and as a potential intervention in aging-related pathologies.
Humanin acts through both extracellular receptor-based signaling and intracellular mechanisms. At the cell surface, it signals through a trimeric receptor complex composed of CNTFR (ciliary neurotrophic factor receptor), WSX-1, and gp130 — the same receptor components used by the IL-6 cytokine family. Intracellularly, Humanin can directly bind and modulate pro-apoptotic proteins including IGFBP-3 and BAX. The combination of extracellular and intracellular activity gives Humanin a multi-pronged anti-apoptotic and anti-inflammatory profile that is being explored across contexts as diverse as Alzheimer’s disease, cardiac protection, type 2 diabetes, and general aging biology.
Humanin can be explored alongside related mitochondrial peptides and neuroprotective compounds in the Peptide Database. Those interested in protocols involving Humanin and related longevity-associated peptides can consult the AI Peptide Coach.
Extracellularly, Humanin signals through a trimeric receptor complex: CNTFR (ciliary neurotrophic factor receptor alpha), WSX-1 (IL-27 receptor alpha, also known as TCCR), and gp130 (the shared signal transducing component of the IL-6 family receptors). This trimeric assembly is similar to the receptor complex used by CNTF itself and by cardiotrophin-like cytokine. When Humanin binds this complex, it induces receptor dimerization and transphosphorylation of the associated Janus kinases — primarily JAK2 — which then phosphorylate and activate STAT3 (Signal Transducer and Activator of Transcription 3).
Phosphorylated STAT3 dimerizes and translocates to the nucleus where it activates transcription of a range of pro-survival, anti-inflammatory, and metabolic target genes. In neurons, STAT3 target genes include anti-apoptotic proteins like BCL-2 and BCL-XL, neurotrophic factors, and mitochondrial biogenesis regulators. In metabolic tissues, STAT3 activation by Humanin improves insulin signaling and glucose homeostasis. In immune cells, this pathway attenuates pro-inflammatory gene expression. The breadth of JAK2/STAT3 signaling explains why Humanin has such wide-ranging effects — it is leveraging one of the most pleiotropic intracellular signaling cascades in cell biology through a receptor that happens to be expressed in almost all tissues.
In addition to its extracellular receptor signaling, Humanin exerts direct intracellular anti-apoptotic effects. The BCL-2 protein family controls the intrinsic (mitochondrial) apoptosis pathway by regulating the balance between pro-apoptotic members (BAX, BAK, BIM, PUMA) and anti-apoptotic members (BCL-2, BCL-XL, MCL-1). When pro-apoptotic signals overwhelm the anti-apoptotic proteins, BAX oligomerizes in the outer mitochondrial membrane, forming pores through which cytochrome c is released. Cytochrome c release triggers caspase activation and irreversible commitment to apoptosis.
Humanin intervenes at multiple points in this cascade. First, STAT3 activation downstream of its receptor upregulates BCL-2 and BCL-XL transcription, increasing the cellular reservoir of anti-apoptotic proteins. Second — and more unusually — Humanin appears to directly interact with BAX and suppress its oligomerization and membrane insertion. This second mechanism is intracellular and does not require receptor binding, suggesting Humanin can enter cells and act directly on the mitochondrial membrane machinery. The combined effect is a cell that is substantially more resistant to apoptotic triggers — which is precisely the state needed in neurons under amyloid-beta challenge or cardiomyocytes under ischemia.
Insulin-like growth factor binding protein 3 (IGFBP-3) is the most abundant IGF binding protein in the circulation and serves as a reservoir that keeps the majority of circulating IGF-1 in a bound, biologically inactive state. IGFBP-3 is itself a signaling molecule with pro-apoptotic activities independent of IGF-1. Humanin was identified as a binding partner of IGFBP-3 through a yeast two-hybrid screen, and subsequent research confirmed that this interaction has functional consequences. When Humanin binds IGFBP-3, it competitively inhibits IGFBP-3’s ability to sequester IGF-1, effectively increasing the fraction of free, bioavailable IGF-1 in the tissue microenvironment.
The increase in bioavailable IGF-1 has significant downstream consequences. IGF-1 is a potent survival and growth factor for neurons, with well-established anti-apoptotic signaling through the PI3K/AKT pathway. In muscle tissue, increased IGF-1 bioavailability supports protein synthesis and satellite cell activation. In the liver and metabolic tissues, IGF-1 signaling improves insulin sensitivity through cross-talk with the insulin receptor pathway. The Humanin-IGFBP-3 interaction thus creates a cascade where Humanin simultaneously neutralizes IGFBP-3’s pro-apoptotic activity and liberates IGF-1 to promote cell survival — a dual-function mechanism that amplifies Humanin’s cytoprotective effects considerably beyond what receptor signaling alone would achieve.
The discovery context of Humanin established amyloid-beta neuroprotection as its primary research focus, and this area remains the best-characterized application. Amyloid-beta oligomers and fibrils — the aggregated forms of the amyloid precursor protein cleavage product — induce neuronal death through multiple mechanisms including mitochondrial dysfunction, oxidative stress, calcium dysregulation, and activation of pro-apoptotic cascades. Humanin protects neurons against all of these insults. In cell culture studies, Humanin pre-treatment dramatically reduces amyloid-beta-induced neuronal death at nanomolar concentrations. In APP/PS1 transgenic mice (a standard Alzheimer’s model), Humanin administration reduced amyloid burden, improved synaptic density, and improved cognitive performance on spatial memory tasks.
The mechanisms behind this protection are multilayered. Humanin directly binds certain amyloid-beta oligomers and may inhibit their cell membrane interaction. Separately, Humanin’s anti-apoptotic signaling through BCL-2 and STAT3 protects mitochondrial function in neurons challenged by amyloid-beta. Additionally, Humanin reduces microglial inflammatory activation in response to amyloid deposits, dampening the neuroinflammatory component of AD pathology. Whether circulating Humanin levels in early AD patients predict disease progression, and whether Humanin supplementation can slow cognitive decline in humans, remain important and as yet unanswered clinical questions.
Myocardial ischemia-reperfusion injury — the paradoxical tissue damage that occurs when blood flow is restored to the heart after a period of ischemia — is mediated in large part by mitochondrial dysfunction, oxidative burst, and cardiomyocyte apoptosis in the reperfusion phase. This is the context where a mitochondrially-derived protective peptide has compelling mechanistic relevance. Research in rodent models of cardiac ischemia-reperfusion has shown that Humanin administration (either pre-ischemia or at reperfusion) significantly reduces infarct size, preserves left ventricular function, and reduces the number of apoptotic cardiomyocytes in the infarct border zone.
The protective mechanism in the heart appears to involve both preservation of mitochondrial membrane potential (preventing the mitochondrial permeability transition pore opening that is central to reperfusion injury) and direct anti-apoptotic effects through BAX inhibition and BCL-2 upregulation. Humanin levels in the myocardium decrease during ischemia, suggesting that the heart’s own Humanin production is overwhelmed under ischemic stress — which makes exogenous Humanin supplementation mechanistically logical. Interest has also developed in Humanin as a potential cardioprotective agent in the context of chemotherapy-induced cardiomyopathy, where doxorubicin and other agents impose direct mitochondrial oxidative stress on cardiomyocytes.
Humanin’s role in metabolic regulation has emerged as a significant research area independent of its neuroprotective and cardioprotective properties. In animal models of type 2 diabetes and diet-induced obesity, Humanin administration improves insulin sensitivity, reduces fasting glucose, and decreases hepatic glucose output. The mechanisms involve STAT3 activation in hepatocytes (which suppresses gluconeogenic gene expression) and improved insulin receptor signaling in both liver and skeletal muscle. Humanin has also been shown to reduce adipogenesis in precursor cells and to protect pancreatic beta cells from glucolipotoxicity — the combination of high glucose and high lipid that drives beta cell failure in type 2 diabetes.
Particularly interesting is the relationship between Humanin and caloric restriction biology. Caloric restriction, the most robust intervention for extending healthy lifespan across species, is associated with improved insulin sensitivity and mitochondrial efficiency. Some evidence suggests that Humanin signaling partially mediates caloric restriction benefits. Centenarian studies have shown that long-lived humans have relatively preserved Humanin levels compared to age-matched controls with normal lifespans — a correlation that is consistent with Humanin as a longevity-associated peptide even if causality has not been established.
A critical observation for the longevity and aging field is that circulating Humanin levels decline systematically with age in humans. This decline has been measured in cross-sectional studies comparing young adults to middle-aged and older individuals, and the pattern is consistent across populations. The age-related decline in Humanin is inversely correlated with markers of metabolic disease risk — lower Humanin is associated with greater insulin resistance, higher inflammatory markers, and worse cognitive performance in older adults. Offspring of centenarians have measurably higher Humanin levels than age-matched controls without exceptional parental longevity, suggesting a genetic component to Humanin regulation that may contribute to familial longevity.
This declining trajectory raises an obvious question: can restoring Humanin levels to a younger physiological range mitigate age-related functional decline? Animal studies in aged rodents suggest the answer may be yes — Humanin supplementation in old mice improves cognitive function, reduces age-associated inflammation, and improves metabolic parameters. Whether these findings translate to humans is a central question for ongoing clinical research. The relationship between mitochondrial function, Humanin production, and the hallmarks of aging (senescence, inflammaging, stem cell exhaustion, mitochondrial dysfunction) positions Humanin at an interesting intersection of mechanistic geroscience.
Several lines of evidence connect Humanin to protection against atherosclerotic vascular disease. In macrophages exposed to oxidized LDL — the initiating event in foam cell formation and plaque development — Humanin reduces apoptosis, inhibits lipid accumulation, and suppresses inflammatory cytokine release. In endothelial cells, Humanin reduces VCAM-1 and ICAM-1 expression (adhesion molecules that recruit inflammatory cells to the vessel wall) and preserves endothelial nitric oxide synthase (eNOS) activity. In ApoE knockout mice fed a high-fat diet (a standard atherosclerosis model), Humanin administration reduced plaque burden and improved plaque stability markers. These findings suggest that age-related Humanin decline may contribute mechanistically to the increased cardiovascular disease risk seen in older populations, and that Humanin restoration could have a vascular protective component independent of its neurological and metabolic effects.
The predominant administration route studied for Humanin in research contexts is subcutaneous injection. Most animal studies have used doses in the range of 2–10 mg/kg, with human equivalent dose extrapolations (using body surface area conversion factors) suggesting substantially lower effective doses in humans. The synthetic form most commonly used in research is S14G-Humanin (HNG) — a variant where serine at position 14 is replaced with glycine, which increases potency by approximately 100-fold and improves stability compared to the native sequence. HNG is sometimes referred to as “Humanin analog” in research contexts and is the form typically used in injection studies due to its superior pharmacokinetic profile. Research dosages using the Peptide Dosage Calculators can help translate animal study doses to human research ranges.
Given Humanin’s primary discovery context in neuroprotection, intranasal delivery has been explored as a route that preferentially targets the CNS via olfactory nerve pathways. The nose-to-brain pathway allows peptides to bypass the blood-brain barrier and reach CNS tissue relatively directly — a route that has been studied for a range of neuroprotective peptides. Intranasal Humanin administration in animal studies has shown CNS distribution and neuroprotective effects with doses substantially lower than those required for equivalent systemic administration. This route is particularly relevant for Alzheimer’s disease applications where brain penetration is the primary goal.
Like most peptides, native Humanin has a limited plasma half-life due to peptidase degradation in the circulation. The S14G modification improves stability considerably. Research has also explored longer-acting formulations including PEGylated Humanin analogs and nanoparticle encapsulation. For systemic applications such as cardiac or metabolic protection, a route that achieves sustained tissue concentrations rather than brief peaks is likely to be most effective. Current research protocols typically use once or twice daily subcutaneous injections of the HNG analog. For metabolic applications, timing relative to meals and circadian variation in insulin sensitivity has not been formally optimized in human studies.
In longevity-focused research contexts, Humanin is sometimes considered alongside other mitochondrial-derived peptides including MOTS-c (another MDP with distinct metabolic effects) and Humanin’s own mitochondrial genome co-inhabitants. MOTS-c, which activates AMPK and shares some metabolic benefits with Humanin, has complementary rather than redundant mechanisms. Some researchers have also explored Humanin in the context of IGF-1 axis optimization, noting that Humanin’s IGFBP-3 binding effectively modulates IGF-1 bioavailability — creating potential interactions with growth hormone secretagogues and GHRH analogs. The AI Peptide Coach can help frame Humanin within broader longevity and anti-aging research protocols.
Humanin and its more potent analog HNG have been studied in numerous animal models without identification of significant toxicological concerns at research doses. The peptide’s endogenous origin as a mitochondrially-derived signaling molecule means it is not a foreign structural entity, and preclinical studies have not shown organ toxicity, hematological abnormalities, or behavioral adverse effects. The anti-apoptotic properties of Humanin theoretically raise the question of whether protecting cells from death could inadvertently protect cancer cells as well — a concern that applies broadly to anti-apoptotic interventions. Some in vitro studies have examined Humanin’s effects in cancer cell lines with mixed results depending on cell type, and this question warrants further investigation before conclusions can be drawn about cancer-related safety.
Humanin’s primary extracellular signaling through JAK2/STAT3 warrants consideration because this pathway, when chronically activated, can theoretically contribute to pathological cell proliferation. Constitutive STAT3 activation is found in many cancers and is considered an oncogenic driver in some contexts. However, the physiological, receptor-mediated STAT3 activation induced by Humanin differs from constitutive aberrant STAT3 activity in terms of magnitude, duration, and cellular context. Nonetheless, this theoretical concern argues for monitoring in research applications — particularly in individuals with known malignancies or pre-malignant conditions — and against indiscriminate long-term use without appropriate clinical oversight. Human studies on extended Humanin administration are not yet available.
Humanin’s ability to displace IGFBP-3 from IGF-1 effectively increases bioavailable IGF-1, which has both beneficial (pro-survival, anabolic, insulin-sensitizing) and potentially double-edged (mitogenic, insulin-like) effects depending on context. Elevated IGF-1 signaling is associated with longevity in some studies but with increased cancer risk in others, reflecting the well-documented complexity of the IGF-1 axis in aging and disease. Individuals with IGF-1-sensitive conditions, acromegaly, or insulin disorders should be particularly cautious with Humanin. Monitoring IGF-1 and IGFBP-3 levels in extended research protocols would provide useful context for understanding the magnitude of this effect in individual users.
This is one of the most fascinating aspects of Humanin’s biology. The human mitochondrial genome is a circular 16.5 kilobase DNA molecule encoding only 37 genes — primarily ribosomal RNAs, transfer RNAs, and 13 proteins that are core subunits of the respiratory chain. For decades, the 16S rRNA gene was considered purely structural — it was thought to encode only ribosomal RNA needed for mitochondrial protein synthesis, with no protein-coding capacity. The discovery of Humanin within a small open reading frame in this gene was therefore genuinely surprising. It implies that the mitochondrial genome contains layers of functional information that hadn’t been recognized, and has since motivated systematic searches for other mitochondrially-encoded peptides — which have yielded other MDPs including MOTS-c, SHLP1-6, and others.
S14G-Humanin (also called HNG) is a synthetic analog of native Humanin in which the serine residue at position 14 of the 24-amino acid sequence is replaced with glycine. This single amino acid substitution dramatically increases the peptide’s potency — approximately 100-fold — and improves its resistance to proteolytic degradation in biological fluids. The exact structural reason for the potency enhancement involves the conformational changes introduced by glycine’s unique flexibility, which appears to optimize receptor binding geometry. HNG has become the standard form used in most research because its superior potency allows meaningful effects at lower doses, and because better stability means more reproducible pharmacokinetics. When researchers publish on “Humanin” in contemporary literature, they often mean HNG unless otherwise specified.
Yes, commercial ELISA kits for circulating Humanin are available and have been used in research studies examining age-related decline and disease associations. Circulating Humanin is detectable in human plasma, though levels are low (in the sub-nanomolar range) and assay sensitivity and specificity can vary between platforms. The most consistent research findings have come from studies using validated liquid chromatography-mass spectrometry (LC-MS) methods that can quantify Humanin with high precision. For clinical research applications, baseline and follow-up Humanin measurement can provide direct evidence of endogenous levels and help contextualize any exogenous supplementation. Centenarian studies that measured Humanin used these quantitative methods to establish the correlation between longevity and preserved Humanin levels.
Humanin was the first MDP discovered, but it is now known to be part of a growing family. MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA-c) is encoded in the 12S rRNA gene (a different mitochondrial gene than Humanin’s 16S rRNA locus) and has distinct but overlapping effects. MOTS-c primarily activates AMPK and improves metabolic function, with particularly strong effects on exercise performance, muscle glucose uptake, and obesity resistance. SHLP1-6 (short humanin-like peptides) are additional MDPs encoded near Humanin in the 16S rRNA gene and have individual anti-apoptotic, anti-aging, and metabolic properties. Collectively, these MDPs appear to function as a mitochondrial stress signaling system — alerting the rest of the cell and potentially distant tissues to mitochondrial status.
Human clinical trial data for exogenous Humanin administration remains limited. The majority of research is preclinical (cell culture and animal models). However, observational human studies have firmly established that circulating Humanin levels are measurable, decline with age, correlate with metabolic health markers, and are elevated in centenarians’ offspring. Phase I safety and pharmacokinetic data for Humanin administration in humans is beginning to emerge, but robust Phase II/III efficacy data is not yet available. The Alzheimer’s disease application has attracted interest for clinical translation, and some research centers have initiated pilot studies. For those following this space, PubMed searches for “Humanin clinical” and “HNG human” will surface the latest relevant publications.
Humanin’s primary effects on the growth axis are indirect, mediated through IGFBP-3 displacement increasing bioavailable IGF-1. It does not directly stimulate GH secretion or act on the GH axis upstream. Testosterone and other sex steroids are not direct targets of Humanin signaling based on current evidence. However, the metabolic improvements associated with Humanin (improved insulin sensitivity, reduced adiposity in obese models, improved mitochondrial function) can indirectly support favorable hormonal environments — since insulin resistance and adiposity negatively impact testosterone in men. Some researchers have noted that the longevity-associated hormonal profiles of centenarians (relatively preserved IGF-1, insulin sensitivity, and sex steroid function) correlate with higher Humanin, but causality has not been established.
This is an important nuance. Humanin’s primary protective effect appears to be against the toxicity of amyloid-beta oligomers — the soluble, early-stage aggregates — rather than against mature fibrillar plaques. Soluble oligomers are now understood to be the most synaptotoxic species in AD, causing synaptic dysfunction and neuronal death long before dense plaques are apparent on imaging. Humanin can directly bind some amyloid-beta oligomeric species and interfere with their membrane interactions, while also protecting neurons from oligomer-induced apoptosis through its downstream signaling. In established disease with significant plaque burden, Humanin may still protect surviving neurons and reduce neuroinflammation but would not be expected to dissolve existing plaques. This positions it as potentially most valuable as a preventive or early-intervention strategy.
The Peptide Database includes Humanin alongside other neuroprotective compounds including Semax, Selank, and Dihexa, as well as metabolic peptides with longevity relevance. For protocol guidance and comparison of mechanisms, the AI Peptide Coach offers contextualized research guidance. The Dosage Calculators can assist with HNG dose conversions between research formats.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.